E22 General Considerations for Patient Preference Studies; International Council for Harmonisation; Draft Guidance for Industry; Availability
Published Date: 2/6/2026
Notice
Summary
The FDA just dropped a draft guide to help drug makers understand how to include patient preferences in their studies. This new guidance will shape how drugs get developed and approved by making sure patients’ voices count. If you’re in the drug biz, get your comments in by April 7, 2026, or risk missing out on influencing the final rules!
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Draft guidance on patient preferences
The FDA released a draft guidance called “E22 General Considerations for Patient Preference Studies” that explains general principles for the use, design, conduct, analysis, and submission of patient preference studies to inform drug development, regulatory submissions, drug approvals, and maintenance of approvals. The ICH Assembly endorsed the draft in November 2025 and the FDA is accepting public comments through April 7, 2026.
Public comment deadline April 7, 2026
Stakeholders who want the FDA to consider their views must submit comments on the draft guidance by April 7, 2026 to ensure the Agency considers those comments before it begins work on the final guidance. Comments can be submitted electronically at https://www.regulations.gov (Docket No. FDA-2026-D-0207) or as written/paper submissions following FDA instructions.
No Paperwork Reduction Act burden
The FDA tentatively concludes that the draft guidance contains no collection of information, so clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required. This means the draft guidance, as written, does not create new information-collection paperwork obligations subject to OMB review.
Guidance is nonbinding and flexible
The FDA states that this draft guidance does not establish legally enforceable responsibilities and represents the Agency's current thinking; sponsors may use alternative approaches if they satisfy applicable statutes and regulations. The final guidance will be reformatted to FDA style and the Agency will consider comments (including on costs or cost savings) as it develops the final version.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Previous / Next Documents
Previous: 2026-02323 — Submission for Office of Management and Budget Review; ACF Performance Progress Report, ACF-OGM-SF-PPR-B
The Administration for Children and Families wants to keep using their Performance Progress Report form for three more years but with fewer questions to make it easier for grantees to fill out. This change affects state, tribal, and local groups who get grants and helps make sure projects stay on track without extra hassle. Comments on these updates are open until March 9, 2026.
Next: 2026-02327 — Combined Notice of Filings #1
The Federal Energy Regulatory Commission got a bunch of filings from energy companies like Arizona Public Service and Duke Energy about changes in their status, refunds, and new agreements. These updates could affect electric rates and services soon, with important comment deadlines mostly in February 2026. If you’re involved in energy or just curious, now’s the time to check out these changes and speak up before the deadlines!